New eczema drug candidate passes first safety hurdle in small trial

NCT ID NCT06193434

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called IBI356 in 99 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check if the drug is safe and how the body processes it. Participants received either a single dose, multiple doses, or a placebo. Results will help decide whether to move to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI356 (an experimental drug given as an infusion)
What this could lead to: If this early trial shows IBI356 is safe, it could lead to larger studies testing whether it helps control atopic dermatitis (eczema) symptoms.
What could go wrong: This is a very early Phase 1 study focused on safety, not on whether the drug works. Many drugs fail in later stages, so it is far too soon to know if IBI356 will be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS PATIENTS HEALTHY PARTICIPANTS

Contacts and locations

Locations

Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, 200443, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.